<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00548587</url>
  </required_header>
  <id_info>
    <org_study_id>E5555-G000-202</org_study_id>
    <secondary_id>2006-000296-15</secondary_id>
    <nct_id>NCT00548587</nct_id>
  </id_info>
  <brief_title>Safety and Tolerability of E5555 and Its Effects on Markers of Intravascular Inflammation in Subjects With Acute Coronary Syndrome</brief_title>
  <official_title>A Randomised, Double-Blind, Placebo-Controlled Study of the Safety and Tolerability of E5555, and Its Effects on Clinical Events and Biomarkers in Patients With Non-ST-Segment Elevation Acute Coronary Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eisai Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eisai Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-center, randomized, double-blind, placebo-controlled study to determine the
      safety and tolerability of E5555 in subjects with Acute coronary syndrome (ACS).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2007</start_date>
  <completion_date type="Actual">August 2009</completion_date>
  <primary_completion_date type="Actual">April 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability</measure>
    <time_frame>Up to 16 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Major Adverse Cardiovascular Events; Platelet Aggregation Inhibition; Holter Monitoring. Exploratory Outcome Measure: effects on endovascular inflammatory processes</measure>
    <time_frame>Up to 16 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">600</enrollment>
  <condition>Acute Coronary Syndrome</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will receive one 50 mg E5555 tablet and two 100 mg placebo tablets, once daily for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will receive one 50 mg placebo tablet, one 100 mg E5555 tablet, and one 100 mg placebo tablet, once daily for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will receive one 50 mg placebo tablet and two 100 mg E5555 tablets, once daily for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive one 50 mg placebo tablet and two 100 mg placebo tablets, once daily for 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>E5555</intervention_name>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        INCLUSION CRITERIA:

          1. Males or Females, 45 - 80 years of age

          2. Presenting with features of non-ST segment elevation ACS (unstable angina or
             Myocardial infarction without persistent ST elevation). and at least one of the
             following two criteria on admission: Cardiac enzymesâ‰¥ ULN for the local institution OR
             ECG changes compatible with ischemia

          3. Randomisation possible within 24 hours of the onset of the most recent symptomatic
             episode.

        EXCLUSION CRITERIA:

          1. History of acquired or congenital bleeding disorder, coagulopathy or platelet
             disorder, or history of pathological bleeding within the last 6 months

          2. History of intracranial bleeding, history of hemorrhagic retinopathy, history of
             recent ischemic stroke or transient ischemic attack, or known structural cerebral
             vascular lesion

          3. Recent trauma, major surgery, Percutaneous coronary intervention or coronary artery
             surgery

          4. Clinically significant haematological, hepatic or renal abnormalities

          5. Patients with some specific ST-segment changes, severe congestive heart failure or
             uncontrolled cardiac arrhythmias at baseline

          6. Recent significant (as determined by the investigator) cardiovascular events
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rafal Ziecina, MD</last_name>
    <role>Study Director</role>
    <affiliation>Eisai Limited</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Beloit Clinic, SC</name>
      <address>
        <city>Beloit</city>
        <state>Wisconsin</state>
        <zip>53511-2230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Brompton Hospital</name>
      <address>
        <city>London</city>
        <zip>SW3 6NP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 22, 2007</study_first_submitted>
  <study_first_submitted_qc>October 22, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 24, 2007</study_first_posted>
  <disposition_first_submitted>May 21, 2013</disposition_first_submitted>
  <disposition_first_submitted_qc>May 21, 2013</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">May 29, 2013</disposition_first_posted>
  <last_update_submitted>January 5, 2016</last_update_submitted>
  <last_update_submitted_qc>January 5, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 4, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute Coronary Syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Acute Coronary Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

